Atai Life Sciences N.V. (NASDAQ:ATAI) saw a downside of -0.63% to close Friday at $1.58 after subtracting -$0.01 on the day. The 5-day average trading volume is 609,860 shares of the company’s common stock. It has gained $1.7500 in the past week and touched a new high 1 time within the past 5 days. An average of 655,885 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,083,068.
ATAI’s 1-month performance is -23.67% or -$0.7000 on its low of $1.5400 reached on 08/18/23. The company’s shares have touched a 52-week low of $1.14 and high of $4.96, with the stock’s rally to the 52-week high happening on 01/04/23. YTD, ATAI has lost -40.60% or -$1.0800 and has reached a new high 2 times. However, the current price is down -68.15% from the 52-week high price.
Valuation Metrics
ATAI stock has a beta of 0.86. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 880.01 while the price-to-book (PB) in the most recent quarter is 1.16.
Atai Life Sciences N.V.’s quick ratio for the period ended June 29 was 13.50, with the current ratio over the same period at 13.50. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.07, while the total debt to equity was 0.07. The trailing 12-month EBITDA margin is -61915.02%. The firm’s gross profit as reported stood at $145.02 million against revenue of $0.23 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -10.84% to -$33.04 million, while revenue of -$33.14 million was -0.3% off the previous quarter. Analysts expected ATAI to announce -$0.21 per share in earnings in its latest quarter, but it posted -$0.21, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$31.78 million. ATAI stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 37.96 million, with total debt at $19.0 million. Shareholders hold equity totaling $166.01 million.
Let’s look briefly at Atai Life Sciences N.V. (ATAI) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 25.85% to suggest the stock is trending oversold, with historical volatility in this time period at 35.79%.
The stock’s 5-day moving average is $1.6220, reflecting a -5.95% or -$0.1000 change from its current price. ATAI is currently trading -24.40% above its 20-day SMA, +15.33% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -15.51% and SMA200 by-46.44%.
Stochastic %K and %D was 9.84% and 9.11% and the average true range (ATR) pointed at 0.1035. The RSI (14) points at 32.78%, while the 14-day stochastic is at 7.29% with the period’s ATR at 0.1122. The stock’s 9-day MACD Oscillator is pointing at -0.0544 and -0.1452 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Atai Life Sciences N.V. (NASDAQ: ATAI), Loop Capital launched coverage with a Buy rating. Analysts offering their rating for ATAI stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ATAI as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 10 have offered a “buy” rating.
What is ATAI’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.10 and a high of $21.00, with their median price target at $11.00. Looking at these predictions, the average price target given by analysts is for Atai Life Sciences N.V. (ATAI) stock is $11.90.
